Investing in Gene-Editing Stocks

Best gene-editing companies to invest in

These are some of the gene-editing companies investors should have on their watch list:

1. Intellia Therapeutics

4. Caribou Biosciences

Investing in gene-editing stocks

• CRISPR is based on the immune system that bacteria have developed to thwart viruses. The technique has been described as a “molecular scissor” honed in the battle of bacteria versus virus over millions of years. When attacked by a virus, bacteria are able to target, slice, and destroy the DNA of the virus.
• In 2012, American biochemist Jennifer Doudna and French microbiologist Emmanuelle Charpentier studied the phenomenon and discovered how CRISPR-associated (Cas) proteins could be used to slice strands of DNA. At the same time, RNA molecules made in a lab could guide Cas proteins to exactly where to cut the DNA. The technique works in any cell and opens the possibility for gene editing in humans, plants, and animals.
• The door is now open for using gene editing as a “one-and-done” treatment for a wide range of deadly and debilitating genetic conditions.
• In his New York Times best-seller The Code Breaker, author Walter Isaacson described CRISPR as changing "the future of the human race." (If you're unfamiliar with the book, you might start by watching The Motley Fool’s former healthcare bureau chief Corinne Cardina interview Isaacson on Fool Live.)
• Both Intellia and CRISPR have found large pharmaceutical partners to help fund development and usher the new treatments to market.
• Beam is pursuing innovations that meaningfully address some of the challenges and shortcomings in CRISPR-Cas9.
• Many investors find gene-editing companies complicated. Other investors find them too volatile, with prices stagnating for long periods and then moving strongly up or down depending on publicity about new research findings or the outcome of clinical trials.
• One approach for starting to invest in gene-editing stocks is to consider a basket strategy of putting money into several companies and watching them progress over several years.
• Billions in market value will be created by companies with the ability to cure diseases.
• For patient, buy-and-hold investors, gene-editing companies provide an opportunity to expand your portfolio during the coming genomic revolution.

Risks and challenges of investing in gene-editing stocks

While investing in gene-editing stocks holds the potential for generative significant returns over the long term, it also comes with several risks and challenges. These include:

• High volatility.
• Capital requirements could lead to the dilution of the value of existing shares.
• Risk of failure in clinical trials.
• Risk of failure in securing regulatory approvals.
• Potential reimbursement hurdles after approval.

How to buy gene-editing stocks

1. Open your brokerage app: Log in to your brokerage account where you handle your investments.
2. Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
3. Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
4. Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
5. Submit your order: Confirm the details and submit your buy order.
6. Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.

FAQ